Makonokaya Lucky, Khumbanyiwa Maggie, Kalitera Louiser U, Chamanga Rachel, Dunga Shalom, Jiah Lilian, Masina Elton, Bhatt Nilesh B, Maphosa Thulani
Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States of America.
South Afr J HIV Med. 2025 May 9;26(1):1692. doi: 10.4102/sajhivmed.v26i1.1692. eCollection 2025.
Viral suppression (VS) rates in children on antiretroviral therapy (ART) are lower than in adults. We described the effect of enhanced adherence counselling (EAC) on VS among children with high HIV viral load accessing dolutegravir (DTG)-based ART in a programme setting in Malawi.
This study evaluated the proportion of children with high viral load on DTG-based ART who re-suppressed following EAC and factors associated with VS post-EAC.
We included all patients aged < 15 years with a high viral load result (> 1000 copies/mL) after taking DTG-based ART for at least 6 months between January 2022 and March 2023, covering 104 healthcare facilities in Malawi. Descriptive statistics summarised the distribution of demographic and clinical characteristics. Multivariable logistic regression determined the factors associated with VS following EAC.
Overall, 1475 participants were enrolled; 884 (59.9%) were aged 10-14 years. A total of 1448 (98.2%) were enrolled in EAC, of whom 787 (54.3%), 308 (21.3%), and 353 (24.4%) completed three, two, and one session(s), respectively. Follow-up HIV viral load results were available for 1091 (74%) participants enrolled in EAC, and 782 (71.7%) achieved VS. Patients from urban areas were less likely to achieve VS post-EAC than those from rural areas (adjusted odds ratio [aOR]: 0.58, 95% confidence interval [CI]: 0.42-0.80).
Nearly three-quarters of children with high viral load on DTG-based regimens achieved VS following EAC. Further research on the other contributors of virologic failure among children in Malawi is required.
接受抗逆转录病毒疗法(ART)的儿童的病毒抑制(VS)率低于成人。我们描述了在马拉维的一个项目环境中,强化依从性咨询(EAC)对接受基于多替拉韦(DTG)的ART且HIV病毒载量高的儿童的VS的影响。
本研究评估了接受基于DTG的ART且病毒载量高的儿童在接受EAC后重新实现病毒抑制的比例以及与EAC后病毒抑制相关的因素。
我们纳入了2022年1月至2023年3月期间在马拉维104个医疗机构中,所有接受基于DTG的ART至少6个月后病毒载量高(>1000拷贝/毫升)的15岁以下患者。描述性统计总结了人口统计学和临床特征的分布。多变量逻辑回归确定了EAC后与病毒抑制相关的因素。
总体而言,共纳入1475名参与者;884名(59.9%)年龄在10 - 14岁。共有1448名(98.2%)参与了EAC,其中787名(54.3%)、308名(21.3%)和353名(24.4%)分别完成了三次、两次和一次咨询。参与EAC的1091名(74%)参与者有随访的HIV病毒载量结果,782名(71.7%)实现了病毒抑制。城市地区的患者在EAC后实现病毒抑制的可能性低于农村地区的患者(调整后的比值比[aOR]:0.58,95%置信区间[CI]:0.42 - 0.80)。
接受基于DTG方案且病毒载量高的儿童中,近四分之三在接受EAC后实现了病毒抑制。需要对马拉维儿童病毒学失败的其他促成因素进行进一步研究。